Eli Lilly partners with Hims & Hers to sell Zepbound and Foundayo via telehealth platform
Eli Lilly announced a partnership with Hims & Hers to make its obesity treatments Zepbound and Foundayo available through the telehealth service.
The arrangement lets patients with a prescription purchase the drugs at the same self-pay prices offered elsewhere, with Foundayo listed at $149 per month and Zepbound at $299 per month.
Hims, which previously sold compounded GLP-1 versions, shifted strategy after a legal challenge from Novo, now focusing on providing FDA-approved weight-loss medicines, mirroring a similar deal it struck with Novo in March.
In separate news, Alnylam Pharmaceuticals said its chief commercial officer Tolga Tanguler will leave the company, prompting a sales leadership change.
This writeup was produced by pharmadog from original reporting by BioPharma Dive.
Original headline: “Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down”
read at BioPharma Dive ↗
comments(0)
5-min edit window · permanent after that